Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From challenge to innovation: a narrative review on innovation in nephrology and hemodialysis randomized trials.

Journal of nephrology·2026
Same author

Skin cancer mortality in Australian and New Zealand kidney transplant recipients: A population-based cohort study using linked health data, 1990-2019.

The British journal of dermatology·2026
Same author

Hemodiafiltration beyond the CONVINCE trial.

Clinical kidney journal·2026
Same author

Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE.

PloS one·2026
Same author

A new chapter, a shared responsibility: building the next phase of Journal of Nephrology and strengthening its editorial community.

Journal of nephrology·2026
Same author

Steroid avoidance or withdrawal for kidney transplant recipients.

The Cochrane database of systematic reviews·2026

Related Experiment Video

Updated: May 16, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Treatment for lupus nephritis.

Lorna Henderson1, Philip Masson, Jonathan C Craig

  • 1Centre for Transplant and Renal Research, Westmead Millennium Institute, The University of Sydney at Westmead, Westmead,Australia. l_k_henderson@hotmail.com.

The Cochrane Database of Systematic Reviews
|December 14, 2012
PubMed
Summary

Mycophenolate mofetil (MMF) is as effective as cyclophosphamide for lupus nephritis remission but safer. MMF also outperforms azathioprine in preventing relapse during maintenance therapy.

More Related Videos

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Related Experiment Videos

Last Updated: May 16, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Cyclophosphamide with corticosteroids is a standard treatment for proliferative lupus nephritis.
  • While effective in reducing mortality, this combination therapy has significant toxicities.
  • Newer agents like mycophenolate mofetil (MMF) offer potential for reduced toxicity with comparable efficacy.

Purpose of the Study:

  • To evaluate the benefits and harms of various immunosuppressive treatments for biopsy-proven proliferative lupus nephritis.
  • This review is an update of previous Cochrane analyses on lupus nephritis treatments.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
  • Included adult and pediatric patients with lupus nephritis classes III, IV, V+III, and V+IV.
  • Data extraction and quality assessment were performed independently by two authors.

Main Results:

  • MMF demonstrated comparable efficacy to intravenous cyclophosphamide in achieving stable kidney function and complete remission of proteinuria.
  • MMF showed a significant reduction in ovarian failure and alopecia compared to cyclophosphamide.
  • In maintenance therapy, MMF was associated with a lower risk of renal relapse than azathioprine.

Conclusions:

  • MMF is a safer alternative to cyclophosphamide for inducing remission in lupus nephritis, with a lower risk of ovarian failure.
  • MMF is more effective than azathioprine for maintenance therapy, reducing the risk of renal relapse.
  • Further adequately powered trials with long-term follow-up are needed to fully define the risks and benefits of specific treatment regimens.